LY2886721 has a number of competitors, including MK-8931 from Merck MRK and Ligand Pharma LGND. As you'll see in the data below, the Lilly drug is inferior to MK-8931 in terms of the reduction of CSF levels of AB1-40 (alpha-beta 1-40) peptide after 14 days of treatment (maximum decline of 74% vs. 94%). Of course we have a long way to go before we have any idea if either drug will be effective in treating Alzheimer's disease.
Click here for data from four abstracts on MK-8931 presented at the 2012 AAIC meeting (see where the 94% figure came from...)